Figure 4
From: Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia
Sex and APOE ε4 effects on disease progression. We analysed differences in cognitive decline by sex and APOE ε4 status. Different-coloured lines indicate women APOE ε4 carriers (red), women APOE ε4 non-carriers (pink), men APOE ε4 carriers (dark blue) or men APOE ε4 non-carriers (light blue). The box plot shows the median value of ADAS-cog 13 was 9.3 for preclinical AD and 17.0 for MCI due to AD. The time differences between APOE ε4 carriers and non-carriers at baseline median ADAS-cog 13 in the MCI due to AD cohort (17.0 points) were 3.9 years for women (10.3 years (APOE ε4 non-carriers)—6.4 years (APOE ε4 carriers)) and 6.5 years for men (13.5 years (APOE ε4 non-carriers)—7.0 years (APOE ε4 carriers)). The estimated equation for each sex and APOE ε4 combination is as follows: ADAS Cog-13 = (2.6131 + 0.0203 × month)2 – 0.5 for women APOE ε4 carriers, = (2.6842 + 0.0121 × month)2 – 0.5 for women APOE ε4 non-carriers, = (3.1198 + 0.0127 × month)2 – 0.5 for men APOE ε4 carriers, = (3.0806 + 0.0068 × month)2 – 0.5 for men APOE ε4 non-carriers. ADAS-cog: Alzheimer's Disease Assessment Scale-cognitive subscale; APOE: Apolipoprotein E.
